만성 신질환 환자에서 새로운 경구용 빈혈 치료제: Prolyl Hydroxylase Inhibitor
New Oral Agent for Treatment of Anemia in Patient with Chronic Kidney Disease: Prolyl Hydroxylase Inhibitor
나기랑,
소속 상세정보
나기랑 ( Na Ki-Ryang )
충남대학교 의과대학 신장내과학교실
Abstract
Hypoxia inducible factor (HIF)-stabilizers are being developed for the renal anemia treatment. This small molecules inhibit prolyl hydroxylase domain (PHD)-containing enzymes, causing HIF activation instead of degradation under the state of normoxia, finally increase production of intrinsic erythropoiesis. Current treatment guidelines suggest that renal anemia should be treated mainly with iron and erythropoiesis stimulating agents (ESAs). But there are several complications and concerns such as hypertension, ESA refractory anemia and increased cardiovascular mortality in using ESAs. Advantages of HIF stabilizers over ESAs are orally available, no dose-up requirement for inflammation. So far new HIF stabilizers showed efficacy and safety in renal anemia treatment. This new therapeutic agent may emerge as a standard treatment option for renal anmia treatment.
키워드
Prolyl hydroxylase inhibitor; Anemia; Hepcidin; ESA
원문 및 링크아웃 정보
등재저널 정보